A Study of Apatinib Plus Tegafur Gimeracil Oteracil in Recurrent/Metastatic Head and Neck Cancers
This is a non-randomized, phase II, open label study of apatinib mesylate tablets plus tegafur gimeracil oteracil potassium capsules in recurrent/metastatic squamous cell carcinoma of head and neck. The primary purpose of this study is to evaluate the efficacy of apatinib mesylate tablets plus tegafur gimeracil oteracil potassium capsules in recurrent/metastatic squamous cell carcinoma of head and neck
Head and Neck Squamous Cell Carcinoma
DRUG: Apatinib Mesylate Tablets|DRUG: Tegafur Gimeracil Oteracil Potassium Capsules
Progression-free survival(PFS), from date of enrollment until date of first documented disease progression or death from any cause, assessed up to 2 years, 2 years|Overall survival, from date of enrollment until date of first death from any cause, assessed up to 2 years, 2 years
Acute toxicity profiles, graded according to the NCI CTCAE version 3.0, Number of participants with treatment-related acute toxicity as assessed weekly by CTCAE v3.0 during the course of treatment, 6 months
This is a non-randomized, phase II, open label study of apatinib mesylate tablets plus tegafur gimeracil oteracil potassium capsules in recurrent/metastatic squamous cell carcinoma of head and neck. The primary purpose of this study is to evaluate the efficacy of apatinib mesylate tablets plus tegafur gimeracil oteracil potassium capsules in recurrent/metastatic squamous cell carcinoma of head and neck